At the Azienda Ospedaliero Universitaria of Parma (AOP) – established by the Emilia-Romagna Regional Health Trust - the Maxillofacial Unit, part of the Surgical Department, provides treatment of trauma, malformations (both congenital and acquired) and above all of head and neck tumors (representing a national center of excellence in the treatment of cervical-cephalic oncologic pathologies). Approximately 200 cancer patients per year are treated with minor or major surgery. A team of 6 surgeons, 8 residents, 2 contract surgeons and several nurses operate in the Unit To ensure the best medical, functional, and cosmetic outcomes for patients, the Maxillofacial Unit adopts an interdisciplinary approach to diagnosing and treating all types and stages of cancers that occur in the cervical-facial district. The Maxillofacial Surgery Unit has acquired expertise in this area of research by leading two national and two EC funded study on technologies for risk prediction for Oral Squamous Cells Carcinomas (precisely, ICT-224483 NeoMark and ICT-611425 OraMod) and has the necessary human and organizational resources to cover all the aspects of the research, including management of investigator-driven trials and management of patients and health data.
Role in BD2Decide
The University Hospital Azienda Ospedaliero Universitaria di Parma coordinates BD2Decide and leads the Clinical and Scientific Research and prospective clinical study. The Hospital Unit Maxillo-Facial Surgery acts as Project and Scientific Coordinator, Pilot Health Institution.
Tito Poli, MD
tito.poli at unipr.it